<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-03-23">March 23, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Marc</forename><surname>Beyer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Skin Cancer Centre Charité</orgName>
								<orgName type="department" key="dep2">Department of Dermatology and Allergy</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Staffan</forename><surname>Vandersee</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Skin Cancer Centre Charité</orgName>
								<orgName type="department" key="dep2">Department of Dermatology and Allergy</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<orgName type="institution">Central German Armed Forces Hospital</orgName>
								<address>
									<settlement>Koblenz</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ioana</forename><surname>Cosagarea</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Klinik und Poliklinik für Dermatologie</orgName>
								<orgName type="department" key="dep2">Allergologie und Venerologie</orgName>
								<orgName type="institution">Universitätsklinikum Essen</orgName>
								<address>
									<settlement>Essen</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rachid</forename><surname>Touba</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Skin Cancer Centre Charité</orgName>
								<orgName type="department" key="dep2">Department of Dermatology and Allergy</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Markus</forename><surname>Möbs</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Skin Cancer Centre Charité</orgName>
								<orgName type="department" key="dep2">Department of Dermatology and Allergy</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute for Pathology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Chalid</forename><surname>Assaf</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Skin Cancer Centre Charité</orgName>
								<orgName type="department" key="dep2">Department of Dermatology and Allergy</orgName>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<address>
									<addrLine>Helios Klinikum Krefeld</addrLine>
									<settlement>Krefeld</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Beyer</forename><forename type="middle">/</forename><surname>Vandersee</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Cosagarea</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Touba</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Möbs</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Assaf</surname></persName>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Department of Dermatology and Allergy Central German Armed Forces Hospital Koblenz</orgName>
								<address>
									<addrLine>Rübenacher Strasse 170</addrLine>
									<postCode>DE-56072</postCode>
									<settlement>Koblenz</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-03-23">March 23, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">0752A0636E441E4BF74D141698F38784</idno>
					<idno type="DOI">10.1159/000443840</idno>
					<note type="submission">Received: September 14, 2015 Accepted: January 6, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:35+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Arsenic trioxide</term>
					<term>Combination therapy</term>
					<term>Sézary syndrome</term>
					<term>Retinoids</term>
					<term>All-trans -retinoic acid</term>
					<term>Bexarotene</term>
					<term>Cutaneous T-cell lymphoma</term>
					<term>Mycosis fungoides</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Cutaneous T-cell lymphomas (CTCL) are characterized by an infiltration of the skin with malignant T cells.</s><s>Curative treatments for aggressive entities such as Sézary syndrome have not been identified yet.</s><s>Arsenic trioxide (AsO 3 ) is used for the treatment of acute promyelocytic leukemia in combination with retinoids.</s><s>As the latter are established treatment options in CTCL, we sought to evaluate the efficacy of AsO 3 for mono-and combination therapy in vitro.</s><s>Analyses for apoptosis, cell cycle inhibition, cytotoxicity and cell viability were made after incubation of CTCL cells with AsO 3 alone or in combination with the retinoids all-trans -retinoic acid or bexarotene.</s><s>While AsO 3 induced apoptosis, retinoids did not at the time point of analysis.</s><s>However, retinoids strongly reduced cell viability.</s><s>Due to the efficient apoptosis induction, AsO 3 might be a potentially suitable agent for CTCL treatment, although this effect was not increased by retinoids.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Sézary syndrome belongs to the group of primary cutaneous T-cell lymphoma (CTCL), characterized by a cutaneous infiltration as well as leukemic distribution of malignant T cells and a 5-year survival of only 24% <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref> .</s><s>Even considering the overall scarcity of CTCL, it is a rare condition with a reported incidence of 0.1/1 million person-years <ref type="bibr" target="#b2">[3]</ref> .</s><s>Despite many of the mechanisms leading to malignancy being still unclear, resistance to apoptosis seems to be one of the major features of disease propagation in CTCL <ref type="bibr">[4]</ref> .</s><s>In this context, overexpression of NF-κB, bcl-2, and c-FLIP among others is known to contribute to apoptosis resistance <ref type="bibr" target="#b5">[5]</ref> .</s><s>Furthermore, it has been shown that agents inducing apoptosis in CTCL cells often act via downregulation of these overexpressed antiapoptotic factors <ref type="bibr" target="#b6">[6,</ref><ref type="bibr" target="#b7">7]</ref> .</s><s>This is of interest, because the initial treatment of CTCL like mycosis fungoides and Sézary syndrome is preferably done with immunomodu-latory agents such as interferon-α, photochemotherapy (PUVA), extracorporeal photopheresis or retinoids like bexarotene, the latter even being able to be delivered topically <ref type="bibr" target="#b8">[8,</ref><ref type="bibr" target="#b9">9]</ref> .</s><s>Although these therapies have proven efficacious, remissions in general are not long lasting.</s><s>Cytoreductive therapies, despite also being effective, achieve neither long-lived remissions nor do they alter the course of disease when used early after diagnosis <ref type="bibr" target="#b10">[10,</ref><ref type="bibr" target="#b11">11]</ref> .</s><s>Furthermore, they impair the immune system that is already afflicted by the lymphoma itself.</s><s>The severity of Sézary syndrome and a limited existing arsenal of treatment options underline the necessity for conducting research on novel therapeutical modalities.</s><s>In this respect, arsenic trioxide (AsO 3 ) is a substance with known efficacy for the treatment of hematologic malignant diseases.</s><s>Having been used since antiquity for a variety of ailments <ref type="bibr" target="#b12">[12]</ref> , AsO 3 has been identified as the effective component of a traditional Chinese medicine in the treatment of acute promyelocytic leukemia (APL) and is nowadays approved for this disease <ref type="bibr" target="#b13">[13]</ref> .</s><s>Furthermore, antineoplastic effects were observed in a variety of tumor cell lines, mostly due to cell cycle arrest or direct induction of apoptosis <ref type="bibr" target="#b14">[14]</ref><ref type="bibr" target="#b15">[15]</ref><ref type="bibr" target="#b16">[16]</ref> .</s><s>Due to this, in particular two factors make this substance a promising agent for CTCL treatment: the first is the fact mentioned above, namely that the mode of action seems to rely on induction of apoptosis and among others downregulates bcl-2 that as stated comediates apoptotic resistance in CTCL <ref type="bibr" target="#b17">[17]</ref> .</s><s>Secondly AsO 3 proved to be particularly effective in APL when being combined with the retinoid all-trans -retinoic acid (ATRA), achieving complete remissions in 11 of 12 patients in a pilot study <ref type="bibr" target="#b18">[18]</ref> .</s><s>Concerning CTCL, in vitro experiments have shown that AsO 3 can induce apoptosis in CTCL cell lines.</s><s>Furthermore, intratumoral injection of AsO 3 led to complete remission in a mouse model of CTCL, and treatment of 2 CTCL patients with AsO 3 led to stable disease in the one and partial remission in the other patient <ref type="bibr" target="#b19">[19,</ref><ref type="bibr" target="#b20">20]</ref> .</s><s>The finding of a favorable combination of AsO 3 and retinoids in APL is especially interesting, as the latter represent a mainstay in CTCL treatment.</s><s>They exert a multitude of effects in a variety of cells, affecting proliferation, differentiation, immune response and apoptosis and act by binding to specific nuclear receptors <ref type="bibr" target="#b21">[21]</ref> .</s><s>Two receptor classes are known, retinoid A receptor (RAR, comprised of three different known types), targeted among others by ATRA, and retinoid X receptor (RXR), the target of bexarotene.</s><s>Studies indicate that in CTCL treatment, but of other malignancies such as melanoma cell lines as well, cell cycle inhibition seems to be the most important antineo-plastic effect of retinoids and to offer the possibility of increased efficacy when combined with AsO 3 <ref type="bibr" target="#b22">[22,</ref><ref type="bibr" target="#b24">23]</ref> .</s><s>These data represented the rationale for in vitro assessing the efficacy and mode of action of AsO 3 alone and in combination with several established retinoids for the treatment of cutaneous lymphoma cell lines.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell Lines and Culture Conditions</head><p><s>The two CTCL cell lines SeAx <ref type="bibr" target="#b25">[24]</ref> and Hut-78 <ref type="bibr" target="#b26">[25]</ref> , both established from patients with Sézary syndrome, were cultured at 37 ° C, 5% CO 2 in RPMI 1640 medium (Invitrogen/Life Technologies) supplemented with L -glutamine, fetal bovine serum, and antibiotics (100 units/ml penicillin, 100 μg/ml streptomycin, all PAA, Austria).</s><s>AsO 3 (Sigma-Aldrich, Germany) stock solution was dissolved in 1 m M NaOH at 30 μ M und diluted in cell culture medium for the final dose.</s><s>ATRA (Sigma-Aldrich) and bexarotene (Calbiochem, USA) were dissolved in dimethylsulfoxide, ascorbic acid and N-acetylcysteine in sterile water.</s><s>For all experiments with single substances, cells were cultured in multiwell plates with the respective substance for 24-72 h.</s><s>For combined treatment of cells with ascorbic acid and N-acetylcysteine, cells were preincubated with the respective substance for 1 h before addition of AsO 3 .</s><s>For combined treatment with retinoids, cells were preincubated with ATRA or bexarotene for 48 h and then treated with AsO 3 for 24 h.</s><s>The respective solvents were used as controls.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell Cycle Analysis and Detection of Apoptosis</head><p><s>Cells were harvested by centrifugation, washed once with cold phosphate-buffered saline, fixed with prechilled 70% ethanol at − 20 ° C for 24 h, and stained for 30 min with phosphate-buffered saline containing 0.1% sodium citrate, 20 μg/ml propidium iodide, 0.2 mg/ml RNase A and 0.1% Triton X-100.</s><s>Cells were then analyzed on a flow FACSCalibur flow cytometer (BD Bioscience) using CellQuest Pro (BD Bioscience), WinMDI 2.9 (Scripps Research Institute, La Jolla, Calif., USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cytotoxicity Assay</head><p><s>Cytotoxicity was determined by measuring the amount of lactate dehydrogenase (LDH) in the cell culture supernatant using the Cytotoxicity Detection Kit from Roche Diagnostics according to the recommendations of the manufacturer.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Apoptosis Detection by DNA Fragmentation ELISA</head><p><s>Apoptosis was measured by detection of DNA fragmentation using the Cell Death Detection Kit (Roche Diagnostics) according to the manufacturer's recommendations.</s><s>Optical density values were normalized by division through the optical density of LDH activity (Cytotoxicity Detection Kit, Roche; see above) of the cell lysate to compensate for different amounts of lysed cells.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell Viability Assay</head><p><s>Cell viability was analyzed with the cell proliferation reagent WST-1 (water-soluble tetrazolium; Roche), as recommended by the manufacturer.</s><s>The results correlate with the number of metabolically active cells.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Arsenic Trioxide and Retinoids in CTCL</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effects of AsO 3 on CTCL Cells</head><p><s>First we tested the effect of AsO 3 on apoptosis induction in CTCL cells.</s><s>To this end, the CTCL cell lines Hut-78 and SeAx were incubated with different concentrations of AsO 3 for 24 h, and the rate of apoptotic cells was determined by flow-cytometric analysis (FACS) of the subG 1 population.</s><s>In both cell lines, the percentage of apoptotic cells increased concentration dependently, becoming significantly different from the control at 2.5 μ M for Hut-78 and at 5 μ M for SeAx cells ( fig. <ref type="figure" target="#fig_0">1 a</ref>).</s><s>To test for cytotoxic effects of AsO 3 on CTCL cells, we conducted an assay analyzing the release of LDH as a parameter for damaged cells.</s><s>Hut-78 cells were incubated as described above, and LDH content in the cell culture supernatant was measured at 24 h.</s><s>The amount of LDH was significantly increased at a concentration of 5 μ M ( fig. <ref type="figure" target="#fig_0">1 b</ref>).</s></p><p><s>The efficacy of AsO 3 for inducing apoptosis depends on the antioxidative potential of cells.</s><s>Prior studies have shown that apoptosis induction by AsO 3 occurs via modulation of the antioxidant glutathione <ref type="bibr" target="#b27">[26]</ref> .</s><s>Furthermore, it has been demonstrated that induction of apoptosis is increased by depletion of intracellular glutathione with ascorbic acid (vitamin C) in cancer cells including lymphoma cell lines <ref type="bibr" target="#b19">[19,</ref><ref type="bibr" target="#b28">27]</ref> but inhibited by N-acetylcysteine, which increases intracellular glutathione levels in carcinoma and myeloma cells <ref type="bibr" target="#b29">[28,</ref><ref type="bibr" target="#b30">29]</ref> .</s></p><p><s>To test if these mechanisms apply to Hut-78 and SeAx cells, both cell lines were incubated with either 1 m M Nacetylcysteine or 100 μ M vitamin C for 1 h before addition of either 2. bation of cells with vitamin C or N-acetylcysteine as a control did not induce apoptosis at the respective concentrations.</s><s>While vitamin C led to a 3-fold increase, N-acetylcysteine led to a 2.2-fold decrease in AsO 3 -induced apoptosis in Hut-78 cells ( fig. <ref type="figure" target="#fig_0">1 c, d</ref>).</s><s>These effects were also seen in the DNA fragmentation ELISA and observed after treatment of SeAx cells (data not shown).</s><s>Due to the demonstration of induction of apoptosis without concomitant cytotoxic effects, we used 2.5 μ M AsO 3 for further experiments.</s><s>The induction of apoptosis at this dose was also confirmed by demonstration of a significant increase in DNA fragmentation in Hut-78 cells after treatment with 2.5 μ M AsO 3 for 24 h.</s><s>It is noteworthy that the dose of 2.5 μ M AsO 3 has been shown to be readily achievable in patients during treatment <ref type="bibr" target="#b31">[30]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effects of the Retinoids ATRA and Bexarotene on CTCL Cells Alone and in Combination with AsO 3</head><p><s>The main scope of our study was to test whether retinoids are able to augment AsO 3 -induced effects in CTCL cells as it is seen in APL.</s><s>For these experiments ATRA, which ligates the RAR and is used as combination partner in APL, and bexarotene, an RXR-specific retinoid approved for the treatment of primary CTCL, were used.</s><s>Hut-78 cells were incubated for 72 h, as this time span was used in previous studies, with 1, 3, 6, 10, and 25 μ M of ATRA or bexarotene <ref type="bibr" target="#b33">[31]</ref> .</s><s>It has to be noted in this re-spect that at the dosages approved for clinical use ATRA and bexarotene readily reach a plasma concentration of about 1 and 3 μ M , respectively, as could be shown in pharmacokinetic studies <ref type="bibr" target="#b34">[32,</ref><ref type="bibr" target="#b35">33]</ref> .</s></p><p><s>To determine the induction of apoptosis by retinoids, the percentage of cells in the subG 1 populations was measured by flow cytometry.</s><s>Surprisingly, a significant reduction was seen after treatment with 1 μ M ATRA and all concentrations tested for bexarotene ( fig. <ref type="figure" target="#fig_1">2 a</ref>).</s><s>For ATRA a dose-dependent increase in apoptosis induction with a significant difference between 1 and 25 μ M was seen.</s></p><p><s>To assess cell viability, we conducted a WST assay, which correlates with the number of metabolically active cells.</s><s>Despite low levels of apoptosis, a significant reduction of cell viability was seen at the concentration of 1 μ M ATRA or bexarotene, which was not increased dose dependently up to 25 μ M ( fig. <ref type="figure" target="#fig_1">2 b</ref>).</s><s>To exclude a cytotoxic effect of the retinoids on CTCL cells, an LDH assay was made and did not demonstrate significant differences in comparison to control treatment (data not shown).</s></p><p><s>As clear dose-dependent effects were not demonstrated for both retinoids, we chose to evaluate the effects in combination with AsO 3 at the minimal and maximal dose of 1 and 25 μ M .</s></p><p><s>Cells were first incubated for 48 h with the retinoid alone and then for another 24 h with the retinoid in combination with 2.5 μ M AsO 3 .</s><s>Analysis of the subG 1 fraction 67 demonstrated that the percentage of apoptotic cells after combination treatment was significantly higher compared to ATRA but significantly lower in comparison to AsO 3 alone.</s><s>However, the overall effects observed were rather small.</s><s>Comparable results were seen with the combination of bexarotene and AsO 3 , though no significant reduction of AsO 3 -induced apoptosis was seen at the dose of 25 μ M ( fig. <ref type="figure" target="#fig_2">3 a</ref>).</s></p><p><s>The WST assay showed that in all settings, treatment led to a decreased cell viability compared to the control.</s><s>While addition of retinoids to AsO 3 resulted in a significant decrease (p &lt; 0.01) compared to the AsO 3 alone, the combination did not further increase retinoid-induced reductions of cell viability ( fig. <ref type="figure" target="#fig_2">3 b</ref>).</s><s>The LDH activity in the cell culture supernatant was measured, and none of the combinations exhibited significant cytotoxic effects (data not shown).</s><s>Regarding the distribution of cells in the different phases of the cell cycle, we observed only a slight reduction in cells in the S phase after ATRA but not bexarotene treatment while an arrest in the G 1 phase was observed for AsO 3 , which was not influenced by preceding retinoid treatment ( fig. <ref type="figure" target="#fig_2">3 c</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Induction of apoptosis and cell cycle arrest are thought to be major mechanisms of treatment modalities used for the treatment of CTCL like retinoids, interferons and photochemotherapy <ref type="bibr" target="#b36">[34]</ref><ref type="bibr" target="#b37">[35]</ref><ref type="bibr" target="#b38">[36]</ref> .</s><s>Previous data on the successful use of AsO 3 in conjunction with the retinoid ATRA in APL led us to the question whether this combination might also prove beneficial in the therapy of CTCL.</s><s>In APL a distinct mutation resulting in a fusion gene of the RAR-α and tumor-propagating genes are thought to represent the target for ATRA.</s><s>Although such a driving mutation has not been demonstrated in CTCL, both ATRA and bexarotene have been reported to be efficient in CTCL treatment and to affect the microenvironment of the tumor cells, e.g. protein expression in keratinocytes <ref type="bibr" target="#b39">[37]</ref><ref type="bibr" target="#b40">[38]</ref><ref type="bibr" target="#b41">[39]</ref><ref type="bibr" target="#b42">[40]</ref><ref type="bibr">[41]</ref> .</s><s>Our results demonstrate that incubation of CTCL cell lines with AsO 3 leads to a dose-dependent increase in apoptosis without cytotoxic side effects at concentrations that can be reached under therapeutical conditions.</s><s>Only at higher concentrations like 5 μ M was LDH significantly increased arguing for a direct cytotoxic effect of AsO 3 at this concentration.</s><s>Additionally, we confirmed the augmenting effects of vitamin C on apoptosis induction and introduce data that N-acetylcysteine also in CTCL cell lines almost completely countermands the effects of AsO 3 underlining the importance of the cell's redox system for both the apoptotic effect of AsO 3 and carcinogenesis in CTCL or in general <ref type="bibr" target="#b45">[42,</ref><ref type="bibr" target="#b46">43]</ref> .</s><s>Furthermore, the concentration of vitamin C used is nearly reached in the plasma under normal nutritional conditions, leading to the question whether a dietarily induced higher uptake could influence the efficacy of treatment <ref type="bibr" target="#b47">[44]</ref> .</s></p><p><s>When investigating the effects of retinoids alone, we found a significant increase in apoptosis neither for ATRA nor for bexarotene after 72 h of treatment.</s><s>This time span has been sufficient in some but not in other reports on apoptosis induction of retinoids in CTCL cells.</s><s>As different working groups have employed varying analytic settings regarding dose range, incubation periods and cell type, the results obtained are not easily comparable.</s><s>In our experiments neither RAR-nor RXR-specific retinoids induced significant apoptosis but reduced cell viability in CTCL cells after treatment for 72 h.</s><s>These observations argue for an antiproliferative effect preceding apoptosis induction as the reduction in cell number was not explained by direct cytotoxic effects.</s><s>This is in line with a paper pointing towards a proliferative arrest at different cell cycle stages by bexarotene <ref type="bibr" target="#b20">[20,</ref><ref type="bibr" target="#b22">22]</ref> .</s><s>Furthermore, induction of apoptosis in vivo could not be demonstrated.</s><s>Finally, other modes of action such as reduction of T-cell migration, e.g.</s><s>via expression of homing receptors expressed by the tumor cells, may also play a role in bexarotene-induced responses seen in CTCL patients <ref type="bibr" target="#b48">[45,</ref><ref type="bibr" target="#b49">46]</ref> .</s><s>In conclusion, in our experiments retinoids did not induce significant alterations of the cell cycle as it has been described before for bexarotene.</s><s>In contrast to a strong G 1 arrest in adult T-cell leukemia cells by AsO 3 treatment, incubation of CTCL cells with AsO 3 led to only a slight increase in the G 1/0 fraction <ref type="bibr" target="#b50">[47,</ref><ref type="bibr" target="#b51">48]</ref> .</s></p><p><s>In combination with AsO 3 both retinoids reduced apoptosis induction by AsO 3 significantly, whereas reduction in cell viability was unaltered in all combinations applied.</s><s>Therefore, our experiments did not demonstrate an additive or synergistic effect with regard to induction of apoptosis or reduction of cell viability.</s><s>Furthermore, we did not observe cytotoxic effects of the combination treatment in vitro at pharmacologically tolerated doses, which correlates with the tolerability of combined ATRA and AsO 3 treatment of APL patients.</s><s>In the literature, AsO 3 has so far only been used in 2 patients with Sézary syndrome or erythrodermic mycosis fungoides, resulting in stable disease and partial remission, respectively.</s><s>These remissions, though, were reported to last for only a week after discontinuation of therapy because of adverse events <ref type="bibr" target="#b19">[19]</ref> .</s><s>These results suggest the necessity of a combination partner other than retinoids, should AsO 3 play a future role in CTCL treatment.</s><s>In adult T-cell leukemia, several studies report on the successful combination of AsO 3 with interferon-α <ref type="bibr" target="#b52">[49,</ref><ref type="bibr" target="#b53">50]</ref> .</s><s>As the latter represents another important substance for CTCL therapy, this might be an interesting combination for future studies.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s><s>Effects of AsO 3 on CTCL cells.</s><s>Values represent means ± SD. a Cell lines Hut-78 (squares) and SeAx (circles) were treated for 24 h with AsO 3 or solvent control (indicated at 0 μ M ) and analyzed subsequently by flow cytometry for the percentage of cells in the subG 1 fraction to determine induction of apoptosis (n = 3, * p &lt; 0.05, * * p &lt; 0.001).</s><s>b Hut-78 cell culture supernatants were analyzed for LDH content by ELISA to determine cytotoxicity (n = 3, * p &lt; 0.001).</s><s>c , d The effect of vitamin C (vit.</s><s>C) and N-acetylcysteine (NAC) on apoptosis induction by 2.5 and 5 μ M AsO 3 , respectively, in Hut-78 cells was analyzed by flow cytometry as described (n = 3, * p &lt; 0.01).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2. Effects of retinoids on CTCL cells.</s><s>Values represent means (n = 9) ± SD. a Hut-78 cells were treated for 72 h with ATRA, bexarotene or solvent control (indicated at 0 μ M ) and analyzed subsequently by flow cytometry for the percentage of cells in the subG 1 fraction to determine induction of apoptosis ( * p &lt; 0.05, * * p &lt; 0.01).</s><s>White bars represent ATRA, gray bars represent bexarotene.</s><s>b Cell viability after retinoid treatment was analyzed with the WST reagent and photometry ( * * p &lt; 0.01); triangles represent ATRA, squares represent bexarotene.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig.3.</s><s>Effects of combination with AsO 3 and retinoids on CTCL cells.</s><s>Hut-78 cells were treated for 72 h with ATRA, bexarotene or solvent control.</s><s>AsO 3 was added in indicated (+) samples at 2.5 μ M for the last 24 h of the incubation period.</s><s>Cells were subsequently analyzed by flow cytometry for the percentage of cells in the subG 1 fraction to determine induction of apoptosis ( a ) or with the WST reagent and photometry to determine cell viability ( b ).</s><s>Significant differences are described in the Results section.</s><s>Bars show means (n = 3) ± SD. c Distribution of cells in the G 0/1 ( ■ ), S ( ▤ ) and G 2 phases ( □ ) was analyzed by FACS.</s><s>Columns represent mean values from triplicates.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>StatisticsStatistics were done using Graph Pad Prism 5 (GraphPad Software Inc., La Jolla, Calif., USA); statistical analyses were done by t test or one-way ANOVA where appropriate.</s><s>Significance levels are given in the text or the figure legends.</s></p></div></figDesc><table /><note><p><s>Skin Pharmacol Physiol 2016;29:63-70 DOI: 10.1159/000443840 65</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Skin Pharmacol Physiol 2016;29:63-70 DOI: 10.1159/000443840</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgment</head><p><s>The study has been financed in part by a research grant from TEVA.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure Statement</head><p><s>Chalid Assaf received honoraria for advisory board meetings and presentations from TEVA and Cephalon oncology.</s><s>Marc Beyer received research grants and honoraria for a presentation from Cephalon oncology and for an advisory board meeting from TEVA.</s><s>Ioana Cosagarea received a travel grant from TEVA.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Survival outcomes and prognostic factors in mycosis fungoides/ Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Agar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Wedgeworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Crichton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ferreira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="4730" to="4739" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">WHO-EORTC classification for cutaneous lymphomas</title>
		<author>
			<persName><forename type="first">R</forename><surname>Willemze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Jaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Burg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cerroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Berti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Swerdlow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="3768" to="3785" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Incidence and survival patterns of cutaneous T-cell lymphomas in the United States</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Imam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Shenoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Flowers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Lechowicz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="752" to="759" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Arsenic Trioxide and Retinoids in CTCL</title>
		<idno type="DOI">10.1159/000443840</idno>
	</analytic>
	<monogr>
		<title level="j">Skin Pharmacol Physiol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="63" to="70" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Reversible resistance to apoptosis in cutaneous T cell lymphoma</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Meech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Edelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Norris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Duke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann NY Acad Sci</title>
		<imprint>
			<biblScope unit="volume">941</biblScope>
			<biblScope unit="page" from="46" to="58" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Nevala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Karenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Vakeva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ranki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="928" to="937" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Inhibition of constitutively activated nuclear factor-kap-paB induces reactive oxygen species-and iron-dependent cell death in cutaneous T-cell lymphoma</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Kiessling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Klemke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Kaminski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Galani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Krammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gülow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="2365" to="2374" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling</title>
		<author>
			<persName><forename type="first">N</forename><surname>Al-Yacoub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Fecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Möbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Plötz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">K</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sterry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Eberle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="2263" to="2274" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Brief S2k guidelines -cutaneous lymphomas</title>
		<author>
			<persName><forename type="first">R</forename><surname>Stadler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Assaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Klemke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nashan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weichenthal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dummer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sterry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dtsch Dermatol Ges</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="19" to="28" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">New and experimental skin-directed therapies for cutaneous lymphomas</title>
		<author>
			<persName><forename type="first">A</forename><surname>Farkas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kemeny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>French</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dummer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Skin Pharmacol Physiol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="322" to="334" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Khot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mccormack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Westerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Twigger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Buelens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Newland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dickinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ritchie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Prince</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="71" to="81" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Kaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Bunn</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Steinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Stocker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Ihde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Fischmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Glatstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Schechter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Phelps</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Foss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">321</biblScope>
			<biblScope unit="page" from="1784" to="1790" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Introduction: the history of arsenic trioxide in cancer therapy</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Antman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="1" to="2" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies</title>
		<author>
			<persName><forename type="first">D</forename><surname>Douer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Tallman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="2396" to="2410" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Endoplasmic reticulum stress mediates the arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">C</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Biochem Cell Biol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="158" to="165" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Arsenic trioxide inhibits growth of human chondrosarcoma cells through G 2 /M arrest and apoptosis as well as autophagy</title>
		<author>
			<persName><forename type="first">G</forename><surname>Jiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="3969" to="3977" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Synergistic effects of arsenic trioxide combined with ascorbic acid in human osteosarcoma MG-63 cells: a systems biology analysis</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">C</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">Y</forename><surname>Maimaiti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">G</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Rev Med Pharmacol Sci</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="3877" to="3888" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As 2 O 3 ) in the treatment of acute promyelocytic leukemia: As 2 O 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARa/PML proteins</title>
		<author>
			<persName><forename type="first">G-Q</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X-G</forename><surname>Shi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="1052" to="1061" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Soignet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Maslak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jhanwar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Calleja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Dardashti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Corso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Deblasio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gabrilove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Scheinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Pandolfi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Warrell</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="page" from="1341" to="1348" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C)</title>
		<author>
			<persName><forename type="first">L</forename><surname>Michel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dupuy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Jean-Louis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Poupon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Viguier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Musette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dubertret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Degos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dombret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bachelez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="881" to="893" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tun-Kyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Z</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Oberholzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Navarini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Hassel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dummer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Döbbeling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1488" to="1494" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Retinoids: mechanisms of action</title>
		<author>
			<persName><forename type="first">P</forename><surname>Berbis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="97" to="103" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<author>
			<persName><forename type="first">N</forename><surname>Nieto-Rementería</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pérez-Yarza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Boyano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Apraiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Izu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Díaz-Pérez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Asumendi</surname></persName>
		</author>
		<title level="m">Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="page" from="519" to="526" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">LRAT overexpression diminishes intracellular levels of biologically active retinoids and reduces retinoid antitumor efficacy in the murine melanoma B16F10 cell line</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Amann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Czaja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Bazhin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rühl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Eichmüller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Merk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Baron</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Skin Pharmacol Physiol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="205" to="212" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">A continuous T-cell line from a patient with Sézary syndrome</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kaltoft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bisballe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Rasmussen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Thestrup-Pedersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Thomsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sterry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol Res</title>
		<imprint>
			<biblScope unit="volume">279</biblScope>
			<biblScope unit="page" from="293" to="298" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Gootenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Ruscetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Mier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gazdar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Gallo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="page" from="1403" to="1418" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system</title>
		<author>
			<persName><forename type="first">J</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Weinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Waxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Jing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="268" to="277" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Arsenicinduced apoptosis in malignant cells in vitro</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Akao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nakagawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="53" to="63" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Arsenic trioxide uses caspase-dependent and caspaseindependent death pathways in myeloma cells</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mccafferty-Grad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Bahlis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Krett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Aguilar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Reis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Boise</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Ther</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1155" to="1164" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Suppression of arsenic trioxide-induced apoptosis in HeLa cells by N-acetylcysteine</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Z</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Park</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cells</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="18" to="25" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">X</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Q</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Ni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">Y</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Q</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">W</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Wang</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Use of arsenic trioxide (As 2 O 3 ) in the treatment of acute promyelocytic leukemia (APL</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Clinical efficacy and pharmacokinetics in relapsed patients</title>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="3354" to="3360" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>II</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Biological effects of bexarotene in cutaneous T-cell lymphoma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Budgin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Newton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wysocka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Zaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Benoit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Rook</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="315" to="321" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Pharmacokinetics of all-trans -retinoic acid administered on an intermittent schedule</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Adamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pluda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Poplack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bauza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Yarchoan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Balis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1238" to="1241" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Initial clinical trial of a selective retinoid X receptor ligand, LGD1069</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Benedetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Rigas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Verret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Pfister</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Straus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Kris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Crisp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Heyman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Loewen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Truglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Warrell</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="790" to="795" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Duvic M: Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action</title>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hazarika</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Weidner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1234" to="1240" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Interferon-alpha induces transient upregulation of c-FLIP through NF-kappaB activation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kanetaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hayashida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hoshika</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Yanase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mizuguchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Cell Res</title>
		<imprint>
			<biblScope unit="volume">314</biblScope>
			<biblScope unit="page" from="246" to="254" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Yoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Rook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Elenitsas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Gasparro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Vowels</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="235" to="242" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Comparison of selective retinoic acid receptor-and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous T-cell lymphoma</title>
		<author>
			<persName><forename type="first">C</forename><surname>Querfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guitart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rademaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Fung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Posten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Kuzel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="25" to="32" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Insights into the all-trans -retinoic acid and arsenic trioxide combination treatment for acute promyelocytic leukemia: a meta-analysis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Haematol</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="101" to="108" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Claudin 2 mRNA and protein are present in human keratinocytes and may be regulated by all-trans -retinoic acid</title>
		<author>
			<persName><forename type="first">D</forename><surname>Telgenhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ramsay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hilz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Slusarewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Shroot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Skin Pharmacol Physiol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="211" to="217" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Different pathways are involved in arsenic-trioxide-induced cell proliferation and growth inhibition in human keratinocytes</title>
		<author>
			<persName><forename type="first">X</forename><surname>Bi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Mi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Skin Pharmacol Physiol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="68" to="78" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">/</forename><surname>Beyer/Vandersee/Cosagarea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">/</forename><surname>Touba</surname></persName>
		</author>
		<author>
			<persName><surname>Möbs</surname></persName>
		</author>
		<idno type="DOI">10.1159/000443840</idno>
	</analytic>
	<monogr>
		<title level="j">Assaf Skin Pharmacol Physiol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="63" to="70" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Bexarotene Worldwide Study Group: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results</title>
		<author>
			<persName><forename type="first">M</forename><surname>Duvic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hymes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Heald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Breneman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Myskowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Crowley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Yocum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="2456" to="2471" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen speciesand iron-dependent cell death in cutaneous T-cell lymphoma</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Kiessling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Klemke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Kaminski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Galani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Krammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gülow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="2365" to="2374" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Reactive molecule species and antioxidative mechanisms in normal skin and skin aging</title>
		<author>
			<persName><forename type="first">U</forename><surname>Wölfle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Seelinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Meinke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lademann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Schempp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Skin Pharmacol Physiol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="316" to="332" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Vitamin C intake and plasma ascorbic acid concentration in adolescents</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Finglas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Loughridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Southon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Nutr</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="563" to="576" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Newton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Bach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Budgin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Benoit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wysocka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Abrams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Rook</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hematol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="792" to="797" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Retinoids bias integrin expression and function in cutaneous T-cell lymphoma</title>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Demarco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Bridges</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="2102" to="2108" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Arsenic trioxide induces apoptosis and cell cycle arrest at G 1 phase to HTLV-1 infected T-cell lines with modulation of bak and Kipl/p27 expression</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ishitsuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kitazono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hanada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Utsunomiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Takeshita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Uozumi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Akiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Arima</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">245</biblScope>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ishitsuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hanada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Uozumi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Utsunomiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Arima</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="649" to="655" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Haidar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hermine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>De Thé</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="278" to="283" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Therapeutic potential of arsenic trioxide with or without interferonalpha for relapsed/refractory adult T-cell leukemia/lymphoma</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ishitsuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Suzumiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aoki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ogata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tamura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="719" to="720" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
